CarMax vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Richmond VA largest US used car retailer (NYSE: KMX) at $26.37B FY2025 revenue; CEO Nash stepping down Dec 2025 with Q3 FY2026 comp sales -8-12% and Edmunds integration competing with Carvana for used vehicle omnichannel retail.
About
CarMax, Inc. is a Richmond, Virginia-based used car retailer — publicly traded on the New York Stock Exchange (NYSE: KMX) as an S&P 500 component — operating as the largest used vehicle retailer in the United States with 250 stores across 109 television markets, 30,000+ associates, and fiscal year 2025 revenue of $26.37 billion (fiscal year ended February 28, 2025). Founded in 1993 as a Circuit City subsidiary in Richmond, CarMax pioneered no-haggle pricing and quality inspections in the used car market, introducing a consumer-friendly alternative to high-pressure dealership tactics. CarMax acquired Edmunds (consumer automotive research) for $404 million in 2021, enhancing digital capabilities and cross-platform vehicle discovery. In late 2025, CarMax announced significant leadership changes: CEO Bill Nash stepped down effective December 1, 2025 after nearly nine years, with Board member David McCreight named Interim President and CEO and former CEO Tom Folliard appointed Interim Executive Chair. The leadership transition came alongside a preliminary Q3 FY2026 outlook showing comparable store used unit sales declining 8-12% amid a soft used car market.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.